84
Participants
Start Date
April 30, 2004
Primary Completion Date
March 31, 2009
Study Completion Date
April 30, 2011
standard GVHD prophylaxis
Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
rituximab
Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
Universitätsklinikum Heidelberg, Heidelberg
Universitätsklinikum Marburg, Marburg
Universitätsklinikum und Poliklinik, Homburg
KMT-Zentrum Medizinische Klinik A, Münster
University Hospital Goettingen, Göttingen
Asklepios Klinik St. Georg, Hamburg
University Hospital Goettingen
OTHER
German High-Grade Non-Hodgkin's Lymphoma Study Group
OTHER
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
OTHER